527 related articles for article (PubMed ID: 18056003)
1. JAK2 exon 12 mutations in polycythemia vera or idiopathic erythrocytosis.
Martínez-Avilés L; Besses C; Alvarez-Larrán A; Cervantes F; Hernández-Boluda JC; Bellosillo B
Haematologica; 2007 Dec; 92(12):1717-8. PubMed ID: 18056003
[TBL] [Abstract][Full Text] [Related]
2. Isolated erythrocytosis in V617F negative patients with JAK2 exon 12 mutations: report of a new mutation.
Bernardi M; Ruggeri M; Albiero E; Madeo D; Rodeghiero F
Am J Hematol; 2009 Apr; 84(4):258-60. PubMed ID: 19229983
[No Abstract] [Full Text] [Related]
3. [Significance of the JAK2V617F mutation in patients with chronic myeloproliferative neoplasia].
Iványi JL; Marton E; Plander M
Orv Hetil; 2011 Nov; 152(45):1795-803. PubMed ID: 22011365
[TBL] [Abstract][Full Text] [Related]
4. Phenotypic variations and new mutations in JAK2 V617F-negative polycythemia vera, erythrocytosis, and idiopathic myelofibrosis.
Williams DM; Kim AH; Rogers O; Spivak JL; Moliterno AR
Exp Hematol; 2007 Nov; 35(11):1641-6. PubMed ID: 17920755
[TBL] [Abstract][Full Text] [Related]
5. JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis.
Scott LM; Tong W; Levine RL; Scott MA; Beer PA; Stratton MR; Futreal PA; Erber WN; McMullin MF; Harrison CN; Warren AJ; Gilliland DG; Lodish HF; Green AR
N Engl J Med; 2007 Feb; 356(5):459-68. PubMed ID: 17267906
[TBL] [Abstract][Full Text] [Related]
6. JAK2 V617F mutation is rare in idiopathic erythrocytosis: a difference from polycythemia vera.
Yoshinaga K; Mori N; Wang YH; Tomita K; Shiseki M; Motoji T
Int J Hematol; 2008 Jul; 88(1):82-87. PubMed ID: 18528646
[TBL] [Abstract][Full Text] [Related]
7. A der(18)t(9;18)(p13;p11) and a der(9;18)(p10;q10) in polycythemia vera associated with a hyperproliferative phenotype in transformation to postpolycythemic myelofibrosis.
Larsen TS; Hasselbalch HC; Pallisgaard N; Kerndrup GB
Cancer Genet Cytogenet; 2007 Jan; 172(2):107-12. PubMed ID: 17213018
[TBL] [Abstract][Full Text] [Related]
8. The JAK2 V617F allele burden in essential thrombocythemia, polycythemia vera and primary myelofibrosis--impact on disease phenotype.
Larsen TS; Pallisgaard N; Møller MB; Hasselbalch HC
Eur J Haematol; 2007 Dec; 79(6):508-15. PubMed ID: 17961178
[TBL] [Abstract][Full Text] [Related]
9. JAK2 exon 12 mutations in cases with JAK2V617F-negative polycythemia vera and primary myelofibrosis.
Maddali M; Kulkarni UP; Ravindra N; Jajodia E; Arunachalam AK; Suresh H; Venkatraman A; George B; Mathews V; Balasubramanian P
Ann Hematol; 2020 May; 99(5):983-989. PubMed ID: 32277273
[TBL] [Abstract][Full Text] [Related]
10. The role of JAK2 V617F mutation, spontaneous erythropoiesis and megakaryocytopoiesis, hypersensitive platelets, activated leukocytes, and endothelial cells in the etiology of thrombotic manifestations in polycythemia vera and essential thrombocythemia.
Bellucci S; Michiels JJ
Semin Thromb Hemost; 2006 Jun; 32(4 Pt 2):381-98. PubMed ID: 16810614
[TBL] [Abstract][Full Text] [Related]
11. Fast and reliable mutation detection of the complete exon 11-15 JAK2 coding region using non-isotopic RNase cleavage assay (NIRCA).
Kambas K; Mitroulis I; Kourtzelis I; Chrysanthopoulou A; Speletas M; Ritis K
Eur J Haematol; 2009 Sep; 83(3):215-9. PubMed ID: 19500139
[TBL] [Abstract][Full Text] [Related]
12. Different involvement of the megakaryocytic lineage by the JAK2 V617F mutation in Polycythemia vera, essential thrombocythemia and chronic idiopathic myelofibrosis.
Hussein K; Brakensiek K; Buesche G; Buhr T; Wiese B; Kreipe H; Bock O
Ann Hematol; 2007 Apr; 86(4):245-53. PubMed ID: 17262192
[TBL] [Abstract][Full Text] [Related]
13. The JAK2(V617F) tyrosine kinase mutation in myelofibrosis with myeloid metaplasia: lineage specificity and clinical correlates.
Tefferi A; Lasho TL; Schwager SM; Steensma DP; Mesa RA; Li CY; Wadleigh M; Gary Gilliland D
Br J Haematol; 2005 Nov; 131(3):320-8. PubMed ID: 16225651
[TBL] [Abstract][Full Text] [Related]
14. Detection of JAK2 exon 12 mutations in 15 patients with JAK2V617F negative polycythemia vera.
Schnittger S; Bacher U; Haferlach C; Geer T; Müller P; Mittermüller J; Petrides P; Schlag R; Sandner R; Selbach J; Slawik HR; Tessen HW; Wehmeyer J; Kern W; Haferlach T
Haematologica; 2009 Mar; 94(3):414-8. PubMed ID: 19252176
[TBL] [Abstract][Full Text] [Related]
15. A sensitive and reliable semi-quantitative real-time PCR assay to detect JAK2 V617F in blood.
Poodt J; Fijnheer R; Walsh IB; Hermans MH
Hematol Oncol; 2006 Dec; 24(4):227-33. PubMed ID: 17006961
[TBL] [Abstract][Full Text] [Related]
16. JAK2V617F monitoring in polycythemia vera and essential thrombocythemia: clinical usefulness for predicting myelofibrotic transformation and thrombotic events.
Alvarez-Larrán A; Bellosillo B; Pereira A; Kerguelen A; Hernández-Boluda JC; Martínez-Avilés L; Fernández-Rodríguez C; Gómez M; Lombardía L; Angona A; Ancochea A; Senín A; Longarón R; Navarro B; Collado M; Besses C
Am J Hematol; 2014 May; 89(5):517-23. PubMed ID: 24458835
[TBL] [Abstract][Full Text] [Related]
17. Identification of JAK2V617F in patients with polycythemia is highly correlated with conventional criteria for diagnosis of polycythemia vera.
Ganly P; Hanrahan V; Baker B; Romeril K
Am J Hematol; 2007 Jan; 82(1):80-2. PubMed ID: 16924638
[TBL] [Abstract][Full Text] [Related]
18. Usefulness of JAK2V617F mutation in distinguishing idiopathic erythrocytosis from polycythemia vera.
Rossi D; Cortini F; Deambrogi C; Barbieri C; Cerri M; Franceschetti S; Conconi A; Capello D; Gaidano G
Leuk Res; 2007 Jan; 31(1):97-101. PubMed ID: 16620973
[TBL] [Abstract][Full Text] [Related]
19. Tumour lysis syndrome after splenic irradiation in a patient with JAK2 V617F post-polycythaemia vera myelofibrosis.
Jain S; Harrison C; McMullin MF; Houston RF
Clin Oncol (R Coll Radiol); 2010 Dec; 22(10):893. PubMed ID: 20692135
[No Abstract] [Full Text] [Related]
20. Long term follow up of 93 families with myeloproliferative neoplasms: life expectancy and implications of JAK2V617F in the occurrence of complications.
Malak S; Labopin M; Saint-Martin C; Bellanne-Chantelot C; Najman A;
Blood Cells Mol Dis; 2012 Oct 15-Dec 15; 49(3-4):170-6. PubMed ID: 22818858
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
